Reviva Pharmaceuticals Holdings Inc. (RVPH) Stock Forecast
Show ratings and price targets of :
Alert
Its only available to paid users.
USD 8.33
(+1,011.11%)
Based on the Reviva Pharmaceuticals Holdings Inc. stock forecast from 3 analysts, the average analyst target price for Reviva Pharmaceuticals Holdings Inc. is USD 8.33 over the next 12 months. Reviva Pharmaceuticals Holdings Inc.’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Reviva Pharmaceuticals Holdings Inc. is Very Bearish, which is based on 0 positive signals and 6 negative signals. At the last closing, Reviva Pharmaceuticals Holdings Inc.’s stock price was USD 0.75. Reviva Pharmaceuticals Holdings Inc.’s stock price has changed by -3.85% over the past week, -27.88% over the past month and -75.17% over the last year.
No recent analyst target price found for Reviva Pharmaceuticals Holdings Inc.
No recent average analyst rating found for Reviva Pharmaceuticals Holdings Inc.
Company Overview Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention"deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California. Read Less
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The...Read More
Frequently Asked Questions About Reviva Pharmaceuticals Holdings Inc. (RVPH) Stock
Based on ratings from 3 analysts Reviva Pharmaceuticals Holdings Inc.'s stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 3 buy, sell and hold ratings.
Unfortunately we do not have enough data on RVPH's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for RVPH is USD 8.33 over the next 12 months. The maximum analyst target price is USD 11 while the minimum anlayst target price is USD 7.
Unfortunately we do not have enough data on RVPH's stock to indicate if its overvalued.
The last closing price of RVPH's stock was USD 0.75.
The most recent market capitalization for RVPH is USD 0.03B.
Based on targets from 3 analysts, the average taret price for RVPH is projected at USD 8.33 over the next 12 months.
This means that RVPH's stock price may go up by +1,011.11% over the next 12 months.
We can't find any ETFs which contains Reviva Pharmaceuticals Holdings Inc.'s stock.
As per our most recent records Reviva Pharmaceuticals Holdings Inc. has 15 Employees.
Reviva Pharmaceuticals Holdings Inc.'s registered address is 10080 N. Wolfe Road, Cupertino, CA, United States, 95014.
You can get more information about it from Reviva Pharmaceuticals Holdings Inc.'s website at https://www.revivapharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Reviva Pharmaceuticals Holdings Inc. (RVPH) Stock
Based on ratings from 3 analysts Reviva Pharmaceuticals Holdings Inc.'s stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 3 buy, sell and hold ratings.
Unfortunately we do not have enough data on RVPH's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for RVPH is USD 8.33 over the next 12 months. The maximum analyst target price is USD 11 while the minimum anlayst target price is USD 7.
Unfortunately we do not have enough data on RVPH's stock to indicate if its overvalued.
The last closing price of RVPH's stock was USD 0.75.
The most recent market capitalization for RVPH is USD 0.03B.
Based on targets from 3 analysts, the average taret price for RVPH is projected at USD 8.33 over the next 12 months.
This means that RVPH's stock price may go up by +1,011.11% over the next 12 months.
We can't find any ETFs which contains Reviva Pharmaceuticals Holdings Inc.'s stock.
As per our most recent records Reviva Pharmaceuticals Holdings Inc. has 15 Employees.
Reviva Pharmaceuticals Holdings Inc.'s registered address is 10080 N. Wolfe Road, Cupertino, CA, United States, 95014.
You can get more information about it from Reviva Pharmaceuticals Holdings Inc.'s website at https://www.revivapharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for RVPH !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
